US Stem Cell Inc (USRM)

[andyshow]

“Bioheart has under promised and over delivered on their MyoCell technology for treating advanced heart failure. Their goal was to beat the performance of CHF drugs and CRT pacers that achieve respectively minus 4 meters decline and 16 to 20 meters improvement in exercise capacity. Bioheart’s 1st gen. MyoCell came in at 95.7 meters improvement over placebo in the controlled, randomized, double blinded Phase II/III MARVEL part I clinical trial - with 33 U.S. centers*. Now entrolling patients in the Phase III MIRROR Trial. No other cell type has beat 63 meters improvement. Cardiac and adipose derived cells score at about 53 meters improvement. Allogenic bone marrow derived cells achieve only 10 meters improvement.” Howard Leonhardt, Executive Chairman of Leonhardt Ventures commented “The 2nd generation Bioheart MyoCell SDF-1 with repeat delivery, nutrient hydrogel and electrical stimulation support is expected to provide even superior results, based on over a dozen years of pre-clinical studies. Bioheart’s MyoCell is the only cell type that has demonstrated an ability to form new contractile muscle in the depths of heart scar tissue. There is over $8 billion spent on CHF drugs each year providing no improvement and only slowing down slightly decline. What is needed is a product like Bioheart’s MyoCell and MyoCell SDF-1 designed to convert heart scar tissue to beating muscle and thus providing true strong improvement. “

https://www.prbuzz.com/business-entrepreneur/268787-leonhardt-increases-stake-in-bioheart-inc-1.html#.VGuZ0T59CWs.linkedin